Open Site Navigation

FEBRUARY 2022

Successful Biomedical Catalyst Funding Award

Partnering with Queens University Belfast (QUB), The Cell and Gene Therapy Catapult (CGTC) and The Scottish National Blood Transfusion Service (SNBTS). VascVersa are awarded BMC funding from IUK.

This highly prestigious and completive award provides a strong endorsement of our technology and team. The BMC grant will fund an almost 1 Million pound 2-year, project which we are leading with support from QUB, SNBTS and CGTC – who are some of the UK’s leading research organisations for cell therapy. The project will accelerate the development of VascVersa’s first product Angicyte.